The MYG1 Knockout UM-UC-3 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population, providing a loss-of-function model for the mitochondrial gene MYG1. This reagent is generated through CRISPR/Cas9-mediated gene disruption in the UM-UC-3 host cell background, yielding a mixed population of gene-edited cells suitable for functional studies. The polyclonal format captures a spectrum of knockout alleles without clonal isolation, enabling researchers to assess the collective impact of MYG1 disruption on cellular phenotypes while avoiding artifacts associated with single-cell cloning.
UM-UC-3 is a well-established human bladder transitional cell carcinoma cell line derived from a male patient. These cells display invasive characteristics and are widely utilized as a preclinical model for bladder cancer biology, including studies on tumor progression, metastasis, and therapeutic resistance. The UM-UC-3 line retains key molecular features of aggressive bladder cancer, making it a relevant platform for interrogating gene function in the context of urothelial carcinoma.
MYG1 encodes a mitochondrial protein that participates in the regulation of apoptosis and cellular proliferation. It acts within the intrinsic apoptotic pathway by influencing mitochondrial membrane integrity and the release of cytochrome c into the cytoplasm. Upstream signals including DNA damage, oxidative stress, and pro-apoptotic stimuli converge on MYG1, which interacts with Bcl-2 family proteins and mitochondrial permeability transition pore components. Upon apoptotic activation, MYG1 facilitates the cytosolic translocation of cytochrome c, triggering the assembly of the apoptosome complex composed of Apaf-1 and pro-Caspase-9. This cascade leads to the activation of Caspase-9, which in turn cleaves and activates the executioner Caspase-3, ultimately targeting PARP and orchestrating cell death.
Knockout of MYG1 in UM-UC-3 cells is anticipated to impair the intrinsic apoptotic machinery, enforcing mitochondrial membrane stabilization and reducing cytochrome c efflux. This disruption likely enhances cell survival and sustains proliferation under stress conditions, mirroring apoptosis resistance mechanisms observed in bladder cancer. The engineered model thus serves as a powerful tool to dissect mitochondrial apoptosis regulation in a disease-relevant cell background, with implications for understanding how bladder cancer cells evade programmed cell death.
These polyclonal knockout cells are suitable for a wide range of research applications, including functional analysis of mitochondrial apoptosis in bladder cancer, identification of novel apoptosis regulators, and drug sensitivity studies targeting apoptotic pathways. Phenotypic screening can be performed using cell viability assays (MTT), mitochondrial membrane potential measurements (JC-1 staining), and cytochrome c release assays. Knockout efficiency can be verified by Sanger sequencing for indel detection and RT-qPCR for transcript ablation, while downstream effects are assessable by Western blotting for MYG1 and cleaved Caspase-3, and flow cytometry for apoptosis (Annexin V/PI). For further information, please contact Ascent Research.
